Financial
FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.
Balance sheet figures not captured from release.
HQ France · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | €649.2m | -0.8% | €30.2m | €9.4m | Cegedim |
Products not yet catalogued.
FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.
Balance sheet figures not captured from release.
Dec 2024: Cegedim's UK GP software subsidiary INPS (Vision) entered administration citing financial difficulties; Cegedim Rx said its pharmacy business was unaffected. In Aug 2025 OneAdvanced bought the Vision EPR assets.
Feb 2026: France's health ministry disclosed a late-2025 cyberattack on Cegedim Santé doctor accounts exposing data of up to 15 million patients, including sensitive notes for about 164,000. Feb 2026: France's top court upheld a 2024 CNIL fine of EUR 800,000. NHS DSPT status not yet checked.
No recalls, safety notices or clinical safety incidents involving Cegedim products found in HSH's search of the last 24 months.
Dec 2024: after Cegedim's INPS subsidiary entered administration, the national rollout of its Vision GP system across Scotland was reported to be on hold; the Vision assets were sold to OneAdvanced in Aug 2025.
No competitors linked yet.